2025 MEDICARE PART D BENEFITS UPDATES FOR IMBRUVICA® PATIENTS

WHAT YOU NEED TO KNOW



UPDATE #1

You Could Be Paying Less For IMBRUVICA® With Capped Out-of-Pocket (OOP) Costs

Starting **January 1, 2025**, patients' 00P costs will be limited to **\$2,000 annually for all** covered Medicare Part D prescription drugs, including IMBRUVICA®.1

UPDATE #2

Spread Out Your Payments With the Medicare Prescription Payment Plan (MPPP)

You may sign up for a new program, the MPPP, which would **spread the OOP costs for your prescription throughout the year into monthly payments with no fees or interest.** Once enrolled, you will be billed directly every month from your plan and pay \$0 at the pharmacy.²

WHAT IS THE MPPP AND HOW DO YOU ENROLL?2



With the MPPP, you can choose to spread your OOP costs over the calendar year



The MPPP allows you to pay monthly instead of paying a large amount all at once



Your Part D insurance plan will offer this option starting October 15, 2024

All Medicare Part D members will be eligible to enroll in the payment plan. You will be able to sign up for the MPPP **beginning October 15th**, while signing up for your Part D 2025 plan. If you miss the open enrollment period, you also have the option to sign up at any point during the year by contacting your Part D insurance provider.

Patients receiving foundation, charity assistance, or LIS/Extra help should NOT enroll in the MPPP.

Contact your insurance provider for more information.



Please see the full **Prescribing Information** for IMBRUVICA®.





HOW ARE YOUR MEDICARE PART D OOP COSTS CHANGING IN 2025?1

	BEFORE REDESIGN	AFTER REDESIGN
Deductible Phase	You pay 100% of your annual deductible	You continue to pay 100% of your annual deductible, which counts towards your \$2,000 OOP maximum
Initial Coverage Phase	You pay a co-payment up to 25% coinsurance , depending on the plan you selected, until you hit the Coverage Gap (or "Donut Hole")	You pay a max of \$2,000 in 00P costs for all covered Medicare Part D prescription drugs, including IMBRUVICA® Once met, there are no additional Medicare Part D drug costs for the remainder of the calendar year, even if you are enrolled in the MPPP
Coverage Gap Phase (The "Donut Hole")	You pay a coinsurance until you reach your OOP drug expense limit	The Coverage Gap (or "Donut Hole") has been eliminated ; you no longer pay OOP costs for IMBRUVICA®
Catastrophic Coverage Phase	You no longer pay OOP costs for drugs	You continue to have no OOP costs for IMBRUVICA®
Payment Program to Manage Drug Costs ²	No – You pay all owed OOP costs at the pharmacy in full	Yes – The new program (MPPP) allows you to spread 00P costs throughout the year and pay \$0 at the pharmacy



THE BENEFIT OF ENROLLING IN THE MPPP AS EARLY AS POSSIBLE IN THE YEAR³

In each scenario, patients pay a max of \$2,000 for all Part D prescriptions combined.

SCENARIO 1 GEORGE WAS PRESCRIBED IMBRUVICA® AND ENROLLED IN THE MPPP IN JANUARY

Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67	\$166.67

SCENARIO 2 GEORGE WAS PRESCRIBED IMBRUVICA® AND ENROLLED IN THE MPPP IN JUNE*

Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	0ct	Nov	Dec
\$0	\$0	\$0	\$0	\$0	\$285.71	\$285.71	\$285.71	\$285.71	\$285.71	\$285.71	\$285.71

^{*}Amounts represented here are monthly maximum caps that the Part D insurance company can legally bill the patient. These calculations are estimates and do not reflect the final monthly patient bill.

SCENARIO 3 GEORGE WAS PRESCRIBED IMBRUVICA® AND WAS NOT ENROLLED IN THE MPPP

Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
\$2,000.00	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0

Medicare Part D patients with high cost-sharing earlier in the plan year are more likely to benefit from the program, having more months to spread their costs across

For help calculating your monthly drug costs and determining if the MPPP is right for you, visit <u>Medicare.gov</u> or talk to your Part D insurance plan.





Please see the full Prescribing Information for IMBRUVICA®.

References: 1. Explaining the prescription drug provisions in the Inflation Reduction Act. KFF. January 24, 2023. Accessed June 1, 2024. https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act 2. Medicare Prescription Payment Plan. CMS. February 29, 2024. Accessed June 1, 2024. https://www.cms.gov/files/document/medicare-prescription-payment-plan-final-part-one-guidance.pdf 3. Technical memorandum on the calculation of the Maximum Monthly Cap on Cost-Sharing Payments under prescription drug plans. CMS. July 17, 2023. Accessed July 18, 2024. https://www.cms.gov/files/document/monthly-cap-cost-sharing-technical-memo-july-2023.pdf



imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140,70 mg capsules